Use of intravitreal rituximab and methotrexate in vitreoretinal lymphoma

Abstract

A 64-year-old Caucasian woman was referred to our hospital after referring vision loss; she had been previously diagnosed with systemic diffuse large B-cell lymphoma. Retinal and optic nerve involvement were found in her right eye, and iris and vitreous involvement were found in her left eye. Vitreoretinal lymphomas (VRL) are rare in medical literature, hence there is a lack of standardised studies regarding therapeutic options in these patients. In our patient, we decided to add intravitreal injections of rituximab and methotrexate to systemic chemotherapy, and to perform pars plana vitrectomy.

Successful Use of Intravitreal Bevacizumab and Methotrexate in a Case of Neovascularization of the Iris and Pseudohypopyon Secondary to Recurrent Diffuse Large B-Cell Lymphoma

“…The treatment options for IOL are limited and include intravitreal and systemic chemotherapy with methotrexate or radiotherapy [ 4 , 5 ]. Intravitreal rituximab has been used in refractory cases or as an adjunct to methotrexate [ 6 ]. If the CNS is also involved, intrathecal methotrexate and cytarabine may also play a role as can rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).…”